Vectibix
(Panitumumab)ApprovedMonoclonal antibody
AmgenPanitumumab is used to treat certain types of colorectal cancer by blocking a protein that helps cancer cells grow and spread.[2] Vectibix is currently approved and in use across 25 indications[4].[1]
Vectibix is one of 526 biologic programs targeting Breast Cancer. It is currently in Approved.
25
Indications
202
Total Trials
42
Active Trials
525
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 25 indications
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Vectibix
AmgenApproved
Adenocard
AstellasPreclinical
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer45 trials
Show 42 more trials
A Clinical Trial of Panitumumab in Combination With FOLFIRI Chemotherapy as Second Line Treatment in Subjects With Metastatic Colorectal Cancer Expressing Wild-type KRAS and Who Had Progressed ≥ 6 Months After the Last Dose of the First Line Chemotherapy
Unknown status·AAssociacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials·Phase 2·NCT01144195·80 enrolled
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Active, not recruiting·—·Phase 2·NCT04117945·22 enrolled
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Terminated·—·Phase 2·NCT02508077·1 enrolled
Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02476045·224 enrolled
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Unknown status·—·Phase 4·NCT02301962·58 enrolled
Colorectal Cancer32 trials
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
Active, not recruiting·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 3·NCT03635021·419 enrolled
Show 29 more trials
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT01704703·72 enrolled
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Active, not recruiting·—·Phase 2·NCT03992456·12 enrolled
Botensilimab and Balstilimab Optimization in Colorectal Cancer
Active, not recruiting·—·Phase 2·NCT06268015·16 enrolled
Head and Neck Cancer7 trials
Esophageal Cancer5 trials
Show 2 more trials
Chemoradiation and Panitumumab for Esophageal Cancer
Completed·—·Phase 2·NCT01077999·78 enrolled
Breast Cancer5 trials
67 more indications
Pancreatic Cancer5 trials
Non-Small Cell Lung Cancer5 trials
Chemotherapy4 trials
Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT00475293·85 enrolled
Esophageal Adenocarcinoma3 trials
Treatment3 trials
Head and Neck Squamous Cell Carcinoma3 trials
Ovarian Cancer3 trials
Squamous Cell Carcinoma3 trials
Locally Advanced3 trials
Metastatic3 trials
Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
Unknown status·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT03751176·31 enrolled
Advanced Solid Tumors3 trials
Cholangiocarcinoma2 trials
Locally Advanced Head and Neck Cancer2 trials
Radiation Therapy2 trials
Adenocarcinoma2 trials
Neoadjuvant Treatment2 trials
Rectal Cancer2 trials
Preoperative Panitumumab and Radiotherapy in Rectal Cancer
Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00973193·20 enrolled
Resistance2 trials
Gastroesophageal Junction Cancer2 trials
Solid Tumors2 trials
RAS Wild Type2 trials
Colon Cancer2 trials
Fluorouracil1 trial
Toxicity1 trial
SKIP - A Double-blind Placebo-controlled Randomized Multicenter Trial of Skin Toxicity Treatment
Terminated·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 2·NCT01418742·11 enrolled
Induction Therapy1 trial
Adult1 trial
Urothelial Carcinoma1 trial
Safety and Efficacy1 trial
Head and Neck Carcinoma1 trial
Cancer of the Head and Neck1 trial
Lung Cancer1 trial
Cervical Cancer1 trial
Advanced Cancer1 trial
Bladder Cancer1 trial
Overall Survival1 trial
Refractory1 trial
Efficacy and Safety1 trial
Platinum-resistant1 trial
Solid Tumor Cancers1 trial
Gallbladder Cancer1 trial
Esophageal Squamous Cell Cancer1 trial
Liver Metastases1 trial
Carcinoid Syndrome1 trial
Study of Panitumumab in the Treatment of Carcinoid Syndrome
Withdrawn·—·Phase 2·NCT01172717
Oral Cavity Cancer1 trial
Advanced Malignant Solid Neoplasm1 trial
Treatment Related Cancer1 trial
HNSCC1 trial
Solid Tumor1 trial
Colorectal Cancer (CRC)1 trial
EGFR NP_005219.2:p.S492R1 trial
Regulatory
FDA Approval Timeline[5]
Sep 27, 2006
VECTIBIX
BLA BLA125147
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Vectibix drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Panitumumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]